Please wait
0000875320VERTEX PHARMACEUTICALS INC / MAS-3ASREX-FILING FEES 0000875320 2025-02-13 2025-02-13 0000875320 1 2025-02-13 2025-02-13 0000875320 2 2025-02-13 2025-02-13 0000875320 3 2025-02-13 2025-02-13 0000875320 4 2025-02-13 2025-02-13 0000875320 5 2025-02-13 2025-02-13
Exhibit 107
Calculation of Filing Fee Tables
Form
S-3
(Form Type)
Vertex Pharmaceuticals Incorporated
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
 
                 
     Security
Type
 
Security
Class
Title(1)
 
Fee
Calculation
or Carry
Forward
Rule
  Amount
Registered 
  Proposed
Maximum 
Offering
Price Per
Unit
  Maximum 
Aggregate
Offering
Price
  Fee
Rate
  Amount of
Registration
Fee
 
Newly Registered Securities
                 
Fees to Be
Paid
  Equity   Common stock, $0.01 par value per share  
Rule 456(b)
and
Rule 457(r)
(3)
  (2)   (2)   (2)   (3)   (3)
                 
    Equity   Preferred stock, $0.01 par value per share  
Rule 456(b)
and
Rule 457(r)
(3)
  (2)   (2)   (2)   (3)   (3)
                 
    Debt   Debt securities  
Rule 456(b)
and
Rule 457(r)
(3)
  (2)   (2)   (2)   (3)   (3)
                 
    Other   Warrants  
Rule 456(b)
and
Rule 457(r)
(3)
  (2)   (2)   (2)   (3)   (3)
                 
    Other   Units  
Rule 456(b)
and
Rule 457(r)
(3)
  (2)   (2)   (2)   (3)   (3)
                 
Fees
Previously Paid
  N/A   N/A   N/A   N/A   N/A   N/A       N/A
 
(1)
Securities registered hereunder may be sold separately, together or as units with other securities registered hereunder.
(2)
Omitted pursuant to Form
S-3
General Instruction II.E. We are registering an indeterminate number of shares of common stock or preferred stock and amount of debt securities as may be issued upon conversion, exchange or exercise, as applicable, of any preferred stock, debt securities, warrants or subscription rights or settlement of any purchase contracts or purchase units, including such shares of common stock or preferred stock as may be issued pursuant to anti-dilution adjustments determined at the time of offering.
(3)
In accordance with Rules 456(b) and 457(r) under the Securities Act, the registrant is deferring payment of the entire registration fee.